Nuvation Bio Inc. (NUVB)
NYSE NYSE Primary 
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nuvation Bio Q2 Earnings Call Highlights
Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients.
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.17 per share a year ago.
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level
I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments.
Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)
Nuvation Bio is upgraded to Buy, driven by Ibtrozi's growing adoption in ROS1+ NSCLC and improved modeling assumptions. Ibtrozi's median response duration approaches 50 months, with first-line patient share now exceeding 50%, supporting significant revenue stacking. Revised SOTP analysis values NUVB equity at $2.1 billion ($6.03/share), about 25% above current prices.
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
